Last night, some 150 cancer researchers and people devoted to the field gathered at the Hilton New York to honor Peter Vogt of The Scripps Research Institute, winner of the 2010 Szent-Györgyi Prize for Progress in Cancer Research. The award was sponsored by the National Foundation for Cancer Research, which was cofounded by Albert Szent-Györgyi in 1973.
John Lechleiter, CEO of Eli Lilly and Company, gave a keynote speech at the award dinner. In it, he said that two main drivers in defeating cancer would be tailored therapies and increased collaboration among pharmas, academia, and more. Establishing those partnerships will necessitate figuring out what information is truly competitive and what can be shared, he said. "The next generation of cancer treatments must be more tailored," he added.
In accepting his award, Vogt's comments reminded attendees of why he's renowned both as a cancer researcher and as a principal investigator. Included in his list of people to thank were the people who have gone through his lab: "The character and quality of a lab are determined by its postdocs and grad students," he said. Vogt's work began with studies of Rous sarcoma virus, but he is best known for his research around P1 3-kinase and elucidating the protein-protein interaction of Myc and Max. Read more about the award in the official announcement.